General American Investors Co. Inc. Raises Stock Position in IDEAYA Biosciences, Inc. $IDYA

General American Investors Co. Inc. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 280,261 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. General American Investors Co. Inc. owned about 0.32% of IDEAYA Biosciences worth $7,626,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of IDYA. Daiwa Securities Group Inc. increased its position in shares of IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares in the last quarter. CWM LLC grew its stake in IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after buying an additional 782 shares during the last quarter. E Fund Management Co. Ltd. increased its position in IDEAYA Biosciences by 7.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock valued at $257,000 after buying an additional 881 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in IDEAYA Biosciences by 39.1% in the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after buying an additional 940 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in IDEAYA Biosciences by 6.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 18,878 shares of the company’s stock worth $397,000 after acquiring an additional 1,191 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on IDYA shares. The Goldman Sachs Group upped their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, October 21st. UBS Group began coverage on shares of IDEAYA Biosciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Royal Bank Of Canada raised their price target on shares of IDEAYA Biosciences from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. JPMorgan Chase & Co. boosted their price objective on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, New Street Research set a $30.00 target price on IDEAYA Biosciences in a research note on Tuesday, October 21st. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.60.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $34.47 on Tuesday. The company’s fifty day moving average price is $35.01 and its 200-day moving average price is $29.41. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $39.28. The firm has a market capitalization of $3.02 billion, a P/E ratio of -18.53 and a beta of 0.05.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, beating the consensus estimate of ($0.12) by $1.45. The business had revenue of $207.83 million during the quarter, compared to analysts’ expectations of $59.98 million. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.